NKBP Share Price

Open 5.71 Change Price %
High 5.71 1 Day -0.12 -2.12
Low 5.54 1 Week 0.00 0.00
Close 5.54 1 Month 0.00 0.00
Volume 6302 1 Year 0.00 0.00
52 Week High 41.39
52 Week Low 28.74
NKBP Important Levels
Resistance 2 5.70
Resistance 1 5.63
Pivot 5.60
Support 1 5.45
Support 2 5.38
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP)

NKBP Technical Analysis 2
As on 6th Feb 2013 NKBP Share Price closed @ 5.54 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.76 & Sell for SHORT-TERM with Stoploss of 5.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
NKBP Target for September
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
NKBP Other Details
Segment EQ
Market Capital 107240808.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
NKBP Address
NKBP
N/A
NKBP Latest News
Interactive Technical Analysis Chart China Nuokang Bio-Pharmaceutical Inc. ( NKBP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on China Nuokang Bio-Pharmaceutical Inc.
NKBP Business Profile
China Nuokang Bio-Pharmaceutical Inc. is a biopharmaceutical company focused on research, development, manufacture, marketing and sales of hospital-based medical products. As of December 31, 2010, it sold a portfolio of 15 products, including four principal products: Baquting, its bleeding control product; Kaitong, its lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; Aiduo, its cardiovascular stress imaging agent, and Aiwen, its anti-arrhythmic agent. Its product pipeline includes three product candidates under development for bleeding control and hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. In February 2013, it announced the completion of the merger with Kingbird Mergerco. Inc., a wholly owned subsidiary of Kingbird Investment Inc. As a result of the merger the Company became a wholly owned subsidiary of Kingbird Investment Inc.